ASCO Gastrointestinal Cancer Symposium

Patients with previously untreated advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma continue to benefit from treatment with nivolumab and chemotherapy.

Long-term survival benefit is seen in patients with treatment-naïve advanced esophageal squamous cell carcinoma who were treated with nivolumab plus chemotherapy or ipilimumab.

Investigators report benefit in patients with CLDN18.2-positive, HER2-negative locally advanced unresectable or metastatic gastric/gastroesophageal junction adenocarcinoma treated with first-line zolbetuximab and mFOLFOX6.

HER-Vaxx with standard-of-care chemotherapy yielded benefit in patients with HER2-overexpressing metastatic or advanced gastric/gastroesophaeal junction adenocarcinoma.

Pre-operative tremelimumab plus durvalumab elicited encouraging safety and activity in patients with microsatellite instability–high resectable gastric or gastroesophageal junction cancer.

The findings, according to a group of researchers, warrant the development of treatments that attack HER2-low advanced gastric cancer.

Zev A. Wainberg, MD, discusses future research efforts for the treatment of patients with advanced gastric cancer.

Ghassan K. Abou-Alfa, MD, detailed the evolution of treatment options for unresectable hepatocellular carcinoma prior to the phase 3 HIMALAYA study and the reasons for launching the trial.

Jun Gong, MD, hosted a Twitter takeover during the 2022 Gastrointestinal Cancers Symposium where he discussed breaking presentations in a #CNRealtimeReport.

Zev A. Wainberg, MD, spoke to the rationale for examining the efficacy of pembrolizumab alone and in combination with chemotherapy for patients with advanced gastric and gastroesophageal junction adenocarcinoma.

Patients with pretreated gastrointestinal stromal tumors who were treated with ripretinib did not reach the primary end point of progression-free survival superiority vs sunitinib in the phase 3 INTRIGUE study.

Patients with recurrent hepatocellular carcinoma after liver transplantation were treated with lenvatinib and saw promising efficacy.

The CheckMate 9X8 trial did not hit the primary end point of progression-free survival superiority with nivolumab plus standard of care vs standard of care alone in metastatic colorectal cancer.

The observational GALAXY study found that use of a ctDNA assay could help determine which patients with colorectal cancer stand to benefit the most by receipt of adjuvant chemotherapy.

Treatment with trastuzumab deruxtecan produced promising efficacy results for patients with HER2-positive metastatic colorectal cancer.

Results from a phase 1/2 study showed that a combination of encorafenib, cetuximab, and nivolumab was well tolerated and yielded promising responses in patients with microsatellite stable BRAFV600E metastatic colorectal cancer.

Although the combination of regorafenib and pembrolizumab failed to meet significance for progression-free survival, an improvement in overall survival and disease control were observed for patients with microsatellite stable colorectal cancer.

Pembrolizumab, binimetinib , and bevacizumab led to deep and durable responses for patients with microsatellite-stable, treatment-refractory metastatic colorectal cancer.

Patients with KRAS-mutant metastatic colorectal cancer who were treated with a combination containing onvansertib had a tolerable safety profile.

Patients with advanced hepatocellular carcinoma achieved notable improvements in survival and responses following treatment with transarterial chemoembolization and lenvatinib.

Interim results of a phase 2 trial found a safe toxicity profile for olaparib plus pembrolizumab in advanced cholangiocarcinoma.

The quality of life was maintained for patients with esophageal cancer plus including gastroesophageal junction adenocarcinoma when treated with pembrolizumab plus chemotherapy.

A safe and tolerable treatment option of transarterial chemoembolization combined with lenvatinib plus sintilimab was given to patients with hepatocellular carcinoma.

Nivolumab in combination with chemotherapy was beneficial vs chemotherapy alone in patients with gastric or gastroesophageal junction cancer at a follow-up of at least 24 months.

Using transarterial chemoembolization, lenvatinib, and PD-1 checkpoint blockade in patients with unresectable advanced hepatocellular carcinoma appears to be a safe and effective option.

A multicenter study found that using lenvatinib for initial treatment helped to increase survival in patients with stage B2 hepatocellular carcinoma.

Although sintilimab improved overall response rates and maintained a tolerable safety profile for patients with metastatic or recurrent pancreatic adenocarcinoma, it did not improve overall or progression-free survival.

Patients with advanced hepatocellular carcinoma achieved a statically significant and clinically meaningful survival benefit following treatment with pembrolizumab and best supportive care in the second line.

Patients with biliary tract cancer who were given the adjuvant oral fluoropyrimidine derivative S-1 had better overall survival compared with surgery alone.

Updated results from a cohort of the KRYSTAL-1 trial spotlight the potential of adagrasib for patients with previously treated KRAS G12C¬–mutant gastrointestinal tumors.